Recently, our group demonstrated that stage II-III CRC patients with high KCNQ1OT1 expression levels exhibit a shorter disease-free survival (DFS) than those with low KCNQ1OT1 expression levels. Here, KCNQ1OT1 is linked to colorectal carcinoma.